Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JLC059
- Development stage
- Preclinical
- Lead developer
- Jecho Laboratories
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JLC059 is an investigational bispecific antibody-drug conjugate (ADC) developed by Jecho Laboratories. It is designed to simultaneously target Glypican-3 (GPC3) and Programmed Death-Ligand 1 (PD-L1). GPC3 is a cell-surface glycoprotein frequently overexpressed in hepatocellular carcinoma (HCC) and other solid tumors, while PD-L1 is a well-characterized immune checkpoint protein. By utilizing a bispecific antibody architecture, JLC059 aims to selectively deliver a cytotoxic payload to tumor cells expressing these markers, potentially increasing therapeutic precision and overcoming resistance mechanisms associated with single-target therapies. As of early 2024, the candidate is in the IND-enabling stage of development for the treatment of solid tumors.
- Other names
- GPC3/PD-L1 ADC
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)GPC3 (Glypican-3)
Beyond the preview
Go deeper on JLC059.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JLC059.